Do you want to skip to content? Skip to content
Contact Us Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本
Convatec Contact Us Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本

29 October 2021

Download the full press release here

PDF Download

 

Q3 performance in line with expectations
& continued strategic progress

Key Points:

  • Q3 Group reported revenue of $511 million was 3.7% higher year on year; up 2.7%1 in constant currency and 2.2%2 on an organic basis.
    • Continued momentum in Advanced Wound Care, modest growth in Ostomy Care and Continence Care, with declines, as expected, in Infusion Care and Critical Care against tough prior year comparatives.
  • Group revenue for the 9 months to 30 September 2021 was up 5.4% on an organic and constant currency basis.
  • Further good progress on our FISBE (Focus, Innovate, Simplify, Build, Execute) strategy to pivot to sustainable and profitable growth:
    • In Continence Care we improved the quality of our HSG business by disposing of the non-core incontinence activities while also signing an agreement to acquire a quality US service provider focused on existing catheter users.
    • To further advance our new product pipeline we have rolled out a consistent new product development and launch process across all business units. We have conducted investment, development, and scale-up gate reviews for new products such as MioAdvance Extended Wear Infusion Sets and the GentleCathTM Air male catheters launching in 2022.
    • We have continued to improve our regulatory processes including optimising the phasing of MDR implementation over an extended timetable.
    • Continuing to make progress and planning further investments in key initiatives such as digital interactions with healthcare professionals and consumers. We are also progressing plans to expand our Global Business Services centre beyond finance to include HR and IT.
  • Strengthened the balance sheet with the successful issuance of $500 million 2029 senior unsecured notes – diversifying Group debt and extending its maturity profile.
  • 2021 full year guidance – We now expect organic2 revenue growth to be towards the upper end of our 3.5-5.0% guidance range with a constant currency adjusted EBIT margin of 18.0-19.0%. Based on current FX this equates to guidance of 17.4-18.4% for the published adjusted EBIT margin.

 

Karim Bitar, Chief Executive Officer, commented:

“During Q3, we continued to drive good momentum in the business and made further strategic progress implementing key transformation initiatives and improving execution.   As expected, the growth in the third quarter slowed from Q2 given the relatively tougher comparatives.  Notwithstanding the continuing uncertainties in the market, particularly around logistics and raw material inflation, for the full year we expect to be towards the upper end of our organic revenue guidance and to meet our EBIT margin guidance. 

“We remain focused on pivoting to sustainable and profitable growth and are making good progress – I am confident in Convatec’s long-term growth prospects.”

Revenue Summary:

 

(...)

Download the full press release here

PDF Download

 

Analysts and Investors

ir@convatec.com

Kate Postans: VP of IR & Corporate Communications  

+44 (0)7826 447807

   

Media

 

Buchanan: Charles Ryland / Chris Lane / Vicky Haynes 

+44 (0)207 466 5000

Press Release

3/5/2022

3/5/2022

Annual Results for the twelve months ended 31 December 2020

Annual Results for the twelve months ended 31 December 2020

3/31/2021

3/31/2021

Convatec awarded contract for Ostomy Products from Vizient, Inc.

Convatec awarded contract for Ostomy Products from Vizient, Inc.

4/29/2021

4/29/2021

Trading update for the three months ended 31 March 2021

Trading update for the three months ended 31 March 2021

6/21/2021

6/21/2021

Global commercial rights signed by Convatec Ltd for ChloraSolv, innovative wound debrider from RLS

Global commercial rights signed by Convatec Ltd for ChloraSolv, innovative wound debrider from RLS

7/30/2021

7/30/2021

Interim Results for the six months ended 30 June 2021

Interim Results for the six months ended 30 June 2021

9/30/2021

9/30/2021

Convatec Group Plc Announces Offering of $500 Million Senior Notes due 2029

Convatec Group Plc Announces Offering of $500 Million Senior Notes due 2029

10/1/2021

10/1/2021

Convatec Group Plc Announces Pricing of $500 Million 3.875% Senior Notes due 2029

Convatec Group Plc Announces Pricing of $500 Million 3.875% Senior Notes due 2029

5/13/2022

5/13/2022

Trading update for the three months ended 30 September 2021

Trading update for the three months ended 30 September 2021

5/13/2022

5/13/2022

Convatec awarded contract for Advanced Wound Care Products from Vizient, Inc.

Convatec awarded contract for Advanced Wound Care Products from Vizient, Inc.

5/13/2022

5/13/2022

25 years of AQUACEL

25 years of AQUACEL

5/13/2022

5/13/2022

Chief Financial Officer succession

Chief Financial Officer succession